EA Pharma Co., Ltd
EA Pharma Co., Ltd., headquartered in Japan, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of innovative gastrointestinal treatments. Founded in 2015, the company has quickly established itself as a leader in its field, focusing on prescription medications that address unmet medical needs. With a strong operational presence in Asia and beyond, EA Pharma is dedicated to enhancing patient outcomes through its unique product offerings, which include advanced formulations and targeted therapies. The company’s commitment to research and development has led to significant milestones, positioning it as a trusted name in the healthcare sector. EA Pharma's dedication to quality and innovation continues to drive its success and reputation in the competitive pharmaceutical landscape.
DitchCarbon Score
How does EA Pharma Co., Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
EA Pharma Co., Ltd's score of 21 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
EA Pharma Co., Ltd, headquartered in Japan, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Eisai Co., Ltd., which provides emissions data and climate commitments cascaded from its parent organisation. Eisai Co., Ltd. has set various climate initiatives, including targets under the Science Based Targets initiative (SBTi), and participates in the Carbon Disclosure Project (CDP) and RE100, which focuses on renewable energy commitments. However, specific reduction targets or achievements for EA Pharma Co., Ltd. are not detailed in the available information. As a subsidiary, EA Pharma's climate commitments are aligned with those of Eisai, reflecting a broader industry commitment to reducing carbon emissions and enhancing sustainability practices. The absence of specific emissions data highlights the need for ongoing transparency and accountability in corporate climate strategies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 49,457,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 55,830,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 456,386,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
EA Pharma Co., Ltd is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
